Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

There’s limited access to California’s cheap insulin, Eli Lilly’s cracking down on black market retatrutide, and new biotech Khartis Therapeutics emerges with $95 million.

Some rather buff fellows at my gym were comparing abdomens today, raving about the bodysculpting wonders of all that illicit “reta.” I imagine they won’t be too pleased about the Lilly news.